Click here to get full coverage on BIIB Stock: Biogen Strengthens Immunology Pipeline In Up To $1B RayThera Deal - Stocktwits

BIIB Stock: Biogen Strengthens Immunology Pipeline In Up To $1B RayThera Deal  Stocktwits

BIIB Stock: Biogen Strengthens Immunology Pipeline In Up To $1B RayThera Deal - Stocktwits

Click here to get full coverage on Biogen pays up to $1B to add RayThera immunology assets - Stock Titan

Biogen pays up to $1B to add RayThera immunology assets  Stock Titan

Biogen pays up to $1B to add RayThera immunology assets - Stock Titan

Click here to get full coverage on Biogen (BIIB) to Acquire RayThera Inc. for Up to $1 Billion - GuruFocus

Biogen (BIIB) to Acquire RayThera Inc. for Up to $1 Billion  GuruFocus

Biogen (BIIB) to Acquire RayThera Inc. for Up to $1 Billion - GuruFocus

Click here to get full coverage on Biogen to Acquire RayThera for Up to $1 Billion to Expand Immunology Pipeline - Quiver Quantitative

Biogen to Acquire RayThera for Up to $1 Billion to Expand Immunology Pipeline  Quiver Quantitative

Biogen to Acquire RayThera for Up to $1 Billion to Expand Immunology Pipeline - Quiver Quantitative

Click here to get full coverage on Biogen (BIIB) Stock After Breakthrough SMA And Lupus Updates Is A 9.4% Undervaluation Story - simplywall.st

Biogen (BIIB) Stock After Breakthrough SMA And Lupus Updates Is A 9.4% Undervaluation Story  simplywall.st

Biogen (BIIB) Stock After Breakthrough SMA And Lupus Updates Is A 9.4% Undervaluation Story - simplywall.st

Click here to get full coverage on Needham Maintains Biogen(BIIB.US) With Buy Rating - Moomoo

Needham Maintains Biogen(BIIB.US) With Buy Rating  Moomoo

Needham Maintains Biogen(BIIB.US) With Buy Rating - Moomoo

Click here to get full coverage on Biogen Inc (BIIB) Institutional Confidence - TradingKey

Biogen Inc (BIIB) Institutional Confidence  TradingKey

Biogen Inc (BIIB) Institutional Confidence - TradingKey

Click here to get full coverage on 3 Overrated Stocks Walking a Fine Line - StockStory

3 Overrated Stocks Walking a Fine Line  StockStory

3 Overrated Stocks Walking a Fine Line - StockStory

Click here to get full coverage on BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag - Yahoo Finance

BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag  Yahoo Finance

BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag - Yahoo Finance

Click here to get full coverage on Biogen targets immunology growth with $1 billion RayThera deal - TradingView

Biogen targets immunology growth with $1 billion RayThera deal  TradingView

Biogen targets immunology growth with $1 billion RayThera deal - TradingView

Click here to get full coverage on BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial - Stocktwits

BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial  Stocktwits

BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial - Stocktwits

Click here to get full coverage on Biogen (BIIB) to Acquire RayThera for Up to $1 Billion - GuruFocus

Biogen (BIIB) to Acquire RayThera for Up to $1 Billion  GuruFocus

Biogen (BIIB) to Acquire RayThera for Up to $1 Billion - GuruFocus

Click here to get full coverage on $BIIB stock rose 2% this week. Here's what we see in our data. - Quiver Quantitative

$BIIB stock rose 2% this week. Here's what we see in our data.  Quiver Quantitative

$BIIB stock rose 2% this week. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Biogen Inc (BIIB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Biogen Inc (BIIB) Earnings Forecast: Future EPS & Revenue Growth Estimates  TradingKey

Biogen Inc (BIIB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Click here to get full coverage on Biogen to Acquire RayThera for Up to $1 Billion - GuruFocus

Biogen to Acquire RayThera for Up to $1 Billion  GuruFocus

Biogen to Acquire RayThera for Up to $1 Billion - GuruFocus

Click here to get full coverage on Biogen Inc (BIIB) Valuation: PE, PB & Fair Value Analysis - TradingKey

Biogen Inc (BIIB) Valuation: PE, PB & Fair Value Analysis  TradingKey

Biogen Inc (BIIB) Valuation: PE, PB & Fair Value Analysis - TradingKey

Click here to get full coverage on BIIB Maintains by Mizuho -- Price Target Lowered to $221 - GuruFocus

BIIB Maintains by Mizuho -- Price Target Lowered to $221  GuruFocus

BIIB Maintains by Mizuho -- Price Target Lowered to $221 - GuruFocus

Click here to get full coverage on Biogen Inc (BIIB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Biogen Inc (BIIB) Technical Analysis: Support, Resistance, Indicators & Moving Averages  TradingKey

Biogen Inc (BIIB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Click here to get full coverage on Why Is Biogen (BIIB) Up 3.8% Since Last Earnings Report? - Yahoo Finance

Why Is Biogen (BIIB) Up 3.8% Since Last Earnings Report?  Yahoo Finance

Why Is Biogen (BIIB) Up 3.8% Since Last Earnings Report? - Yahoo Finance

Click here to get full coverage on Biogen Inc (BIIB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Biogen Inc (BIIB) Risk Assessment: Volatility, Financial Risk & Investment Risk  TradingKey

Biogen Inc (BIIB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Click here to get full coverage on Biogen (BIIB) Expands Immunology Portfolio with $1B RayThera Acquisition - Blockonomi

Biogen (BIIB) Expands Immunology Portfolio with $1B RayThera Acquisition  Blockonomi

Biogen (BIIB) Expands Immunology Portfolio with $1B RayThera Acquisition - Blockonomi

Click here to get full coverage on Biogen Inc. (BIIB) Stock Analysis: Navigating a 10% Upside Potential with Strategic Collaborations - DirectorsTalk Interviews

Biogen Inc. (BIIB) Stock Analysis: Navigating a 10% Upside Potential with Strategic Collaborations  DirectorsTalk Interviews

Biogen Inc. (BIIB) Stock Analysis: Navigating a 10% Upside Potential with Strategic Collaborations - DirectorsTalk Interviews

Click here to get full coverage on Biogen to acquire RayThera for $1 billion - TradingView

Biogen to acquire RayThera for $1 billion  TradingView

Biogen to acquire RayThera for $1 billion - TradingView

Click here to get full coverage on Biogen to Acquire RayThera for Up to $1B - Moomoo

Biogen to Acquire RayThera for Up to $1B  Moomoo

Biogen to Acquire RayThera for Up to $1B - Moomoo

Click here to get full coverage on Biogen Stock (BIIB) Opinions on Congressional Purchases and Analyst Upgrade - Moomoo

Biogen Stock (BIIB) Opinions on Congressional Purchases and Analyst Upgrade  Moomoo

Biogen Stock (BIIB) Opinions on Congressional Purchases and Analyst Upgrade - Moomoo

Click here to get full coverage on A Look At Biogen (BIIB) Valuation After New Breakthrough SMA Nod And Positive Lupus Phase 3 Data - Yahoo Finance

A Look At Biogen (BIIB) Valuation After New Breakthrough SMA Nod And Positive Lupus Phase 3 Data  Yahoo Finance

A Look At Biogen (BIIB) Valuation After New Breakthrough SMA Nod And Positive Lupus Phase 3 Data - Yahoo Finance

Click here to get full coverage on Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Palvella Therapeutics (PVLA) - The Globe and Mail

Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Palvella Therapeutics (PVLA)  The Globe and Mail

Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Palvella Therapeutics (PVLA) - The Globe and Mail

Click here to get full coverage on Biogen Expects to Close Deal in 3Q - Moomoo

Biogen Expects to Close Deal in 3Q  Moomoo

Biogen Expects to Close Deal in 3Q - Moomoo

Click here to get full coverage on Should Biogen’s (BIIB) New SMA Breakthrough and Lupus Data Prompt a Fresh Look From Investors? - Yahoo Finance

Should Biogen’s (BIIB) New SMA Breakthrough and Lupus Data Prompt a Fresh Look From Investors?  Yahoo Finance

Should Biogen’s (BIIB) New SMA Breakthrough and Lupus Data Prompt a Fresh Look From Investors? - Yahoo Finance

Click here to get full coverage on Biogen (NASDAQ: BIIB) director granted 1,505-share equity compensation award - Stock Titan

Biogen (NASDAQ: BIIB) director granted 1,505-share equity compensation award  Stock Titan

Biogen (NASDAQ: BIIB) director granted 1,505-share equity compensation award - Stock Titan

Click here to get full coverage on Biogen (NASDAQ: BIIB) awards 1,505 RSUs to company director - Stock Titan

Biogen (NASDAQ: BIIB) awards 1,505 RSUs to company director  Stock Titan

Biogen (NASDAQ: BIIB) awards 1,505 RSUs to company director - Stock Titan

Click here to get full coverage on 3 Reasons to Avoid BIIB and 1 Stock to Buy Instead - Yahoo Finance

3 Reasons to Avoid BIIB and 1 Stock to Buy Instead  Yahoo Finance

3 Reasons to Avoid BIIB and 1 Stock to Buy Instead - Yahoo Finance

Click here to get full coverage on Biogen (BIIB) Stock Trades Up, Here Is Why - Yahoo Finance

Biogen (BIIB) Stock Trades Up, Here Is Why  Yahoo Finance

Biogen (BIIB) Stock Trades Up, Here Is Why - Yahoo Finance

Click here to get full coverage on Biogen (NASDAQ: BIIB) director receives 2,005 restricted stock unit award - Stock Titan

Biogen (NASDAQ: BIIB) director receives 2,005 restricted stock unit award  Stock Titan

Biogen (NASDAQ: BIIB) director receives 2,005 restricted stock unit award - Stock Titan

Click here to get full coverage on BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire

BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm  GlobeNewswire

BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire

Click here to get full coverage on Biogen (NASDAQ: BIIB) grants director 1,505 RSUs vesting by 2026 - Stock Titan

Biogen (NASDAQ: BIIB) grants director 1,505 RSUs vesting by 2026  Stock Titan

Biogen (NASDAQ: BIIB) grants director 1,505 RSUs vesting by 2026 - Stock Titan

Click here to get full coverage on Biogen Inc. (BIIB) Gets Upgraded by UBS on Upcoming Pipeline Catalysts - Yahoo Finance

Biogen Inc. (BIIB) Gets Upgraded by UBS on Upcoming Pipeline Catalysts  Yahoo Finance

Biogen Inc. (BIIB) Gets Upgraded by UBS on Upcoming Pipeline Catalysts - Yahoo Finance

Click here to get full coverage on Biogen (BIIB) director Lloyd Minor receives 1,505-share equity award in Form 4 filing - Stock Titan

Biogen (BIIB) director Lloyd Minor receives 1,505-share equity award in Form 4 filing  Stock Titan

Biogen (BIIB) director Lloyd Minor receives 1,505-share equity award in Form 4 filing - Stock Titan

Click here to get full coverage on Biogen (BIIB) director receives 1,505 restricted stock units in grant - Stock Titan

Biogen (BIIB) director receives 1,505 restricted stock units in grant  Stock Titan

Biogen (BIIB) director receives 1,505 restricted stock units in grant - Stock Titan

Click here to get full coverage on Biogen (NASDAQ: BIIB) director Jesus B. Mantas awarded 1,505-share stock grant - Stock Titan

Biogen (NASDAQ: BIIB) director Jesus B. Mantas awarded 1,505-share stock grant  Stock Titan

Biogen (NASDAQ: BIIB) director Jesus B. Mantas awarded 1,505-share stock grant - Stock Titan

Click here to get full coverage on Biogen (BIIB) director Menelas Pangalos receives stock grant and exercises 2,370 RSUs - Stock Titan

Biogen (BIIB) director Menelas Pangalos receives stock grant and exercises 2,370 RSUs  Stock Titan

Biogen (BIIB) director Menelas Pangalos receives stock grant and exercises 2,370 RSUs - Stock Titan

Click here to get full coverage on BIIB or TECH: Which Is the Better Value Stock Right Now? - Yahoo Finance

BIIB or TECH: Which Is the Better Value Stock Right Now?  Yahoo Finance

BIIB or TECH: Which Is the Better Value Stock Right Now? - Yahoo Finance

Click here to get full coverage on Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation  ACCESS Newswire

Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Click here to get full coverage on Is Biogen Inc. (BIIB) one of the Best Biotech Stocks to Invest In According to Billionaire Steve Cohen? - Yahoo Finance

Is Biogen Inc. (BIIB) one of the Best Biotech Stocks to Invest In According to Billionaire Steve Cohen?  Yahoo Finance

Is Biogen Inc. (BIIB) one of the Best Biotech Stocks to Invest In According to Billionaire Steve Cohen? - Yahoo Finance

Click here to get full coverage on Biogen Inc. (BIIB) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance

Biogen Inc. (BIIB) Tops Q1 Earnings and Revenue Estimates  Yahoo Finance

Biogen Inc. (BIIB) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance

Click here to get full coverage on [Form 4] BIOGEN INC. Insider Trading Activity - Stock Titan

[Form 4] BIOGEN INC. Insider Trading Activity  Stock Titan

[Form 4] BIOGEN INC. Insider Trading Activity - Stock Titan

Click here to get full coverage on $BIIB stock is up 2% today. Here's what we see in our data. - Quiver Quantitative

$BIIB stock is up 2% today. Here's what we see in our data.  Quiver Quantitative

$BIIB stock is up 2% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on (BIIB) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

(BIIB) as a Liquidity Pulse for Institutional Tactics  Stock Traders Daily

(BIIB) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Click here to get full coverage on Is It Time To Reassess Biogen (BIIB) After Its Strong One Year Share Price Rally - Yahoo Finance

Is It Time To Reassess Biogen (BIIB) After Its Strong One Year Share Price Rally  Yahoo Finance

Is It Time To Reassess Biogen (BIIB) After Its Strong One Year Share Price Rally - Yahoo Finance

Click here to get full coverage on Is It Time To Reconsider Biogen (BIIB) After Its 50% One Year Share Price Jump - Yahoo Finance

Is It Time To Reconsider Biogen (BIIB) After Its 50% One Year Share Price Jump  Yahoo Finance

Is It Time To Reconsider Biogen (BIIB) After Its 50% One Year Share Price Jump - Yahoo Finance

Click here to get full coverage on Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biogen Inc. (BIIB) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biogen Inc. (BIIB) and Encourages Investors to Learn More About the Investigation  ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biogen Inc. (BIIB) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Click here to get full coverage on BIIB stock: Biogen strengthens immunology pipeline in up to $1B RayThera deal - MSN

BIIB stock: Biogen strengthens immunology pipeline in up to $1B RayThera deal  MSN

BIIB stock: Biogen strengthens immunology pipeline in up to $1B RayThera deal - MSN

Click here to get full coverage on New Analyst Forecast: $BIIB Given $255 Price Target - Quiver Quantitative

New Analyst Forecast: $BIIB Given $255 Price Target  Quiver Quantitative

New Analyst Forecast: $BIIB Given $255 Price Target - Quiver Quantitative

Click here to get full coverage on The Bear Case: How BIIB Behaves During Market Shocks - Trefis

The Bear Case: How BIIB Behaves During Market Shocks  Trefis

The Bear Case: How BIIB Behaves During Market Shocks - Trefis

Click here to get full coverage on Did FDA Breakthrough Status for Salanersen Just Shift Biogen's (BIIB) Long-Term SMA Strategy? - simplywall.st

Did FDA Breakthrough Status for Salanersen Just Shift Biogen's (BIIB) Long-Term SMA Strategy?  simplywall.st

Did FDA Breakthrough Status for Salanersen Just Shift Biogen's (BIIB) Long-Term SMA Strategy? - simplywall.st

Click here to get full coverage on Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline - Yahoo Finance

Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline  Yahoo Finance

Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline - Yahoo Finance

Click here to get full coverage on Should Value Investors Buy Biogen (BIIB) Stock? - Yahoo Finance

Should Value Investors Buy Biogen (BIIB) Stock?  Yahoo Finance

Should Value Investors Buy Biogen (BIIB) Stock? - Yahoo Finance

Click here to get full coverage on Biogen (NASDAQ: BIIB) posts 2026 director and proposal vote tallies - Stock Titan

Biogen (NASDAQ: BIIB) posts 2026 director and proposal vote tallies  Stock Titan

Biogen (NASDAQ: BIIB) posts 2026 director and proposal vote tallies - Stock Titan

Click here to get full coverage on Why Biogen (BIIB) Could Beat Earnings Estimates Again - Yahoo Finance

Why Biogen (BIIB) Could Beat Earnings Estimates Again  Yahoo Finance

Why Biogen (BIIB) Could Beat Earnings Estimates Again - Yahoo Finance

Click here to get full coverage on What Makes Biogen (BIIB) an Attractive Long-Term Holding? - Yahoo Finance

What Makes Biogen (BIIB) an Attractive Long-Term Holding?  Yahoo Finance

What Makes Biogen (BIIB) an Attractive Long-Term Holding? - Yahoo Finance

Click here to get full coverage on 2026-06-15 | Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:BIIB | Press Release - Stockhouse

2026-06-15 | Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:BIIB | Press Release  Stockhouse

2026-06-15 | Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:BIIB | Press Release - Stockhouse

Click here to get full coverage on Assessing Biogen (BIIB) Valuation After Breakthrough Therapy Status And Positive Lupus Trial Data - Sahm

Assessing Biogen (BIIB) Valuation After Breakthrough Therapy Status And Positive Lupus Trial Data  Sahm

Assessing Biogen (BIIB) Valuation After Breakthrough Therapy Status And Positive Lupus Trial Data - Sahm

Click here to get full coverage on Biogen to Report Second Quarter 2026 Financial Results July 29, 2026 - Moomoo

Biogen to Report Second Quarter 2026 Financial Results July 29, 2026  Moomoo

Biogen to Report Second Quarter 2026 Financial Results July 29, 2026 - Moomoo

Click here to get full coverage on Biogen Inc. (NASDAQ: BIIB) Navigates Alzheimer’s Drug Trajectory After Leqembi Updates - foreignpolicyjournal.com

Biogen Inc. (NASDAQ: BIIB) Navigates Alzheimer’s Drug Trajectory After Leqembi Updates  foreignpolicyjournal.com

Biogen Inc. (NASDAQ: BIIB) Navigates Alzheimer’s Drug Trajectory After Leqembi Updates - foreignpolicyjournal.com

Click here to get full coverage on BIIB Investor Alert: Levi & Korsinsky Investigates Biogen Inc. (BIIB) for Potential Securities Fraud - Business Wire

BIIB Investor Alert: Levi & Korsinsky Investigates Biogen Inc. (BIIB) for Potential Securities Fraud  Business Wire

BIIB Investor Alert: Levi & Korsinsky Investigates Biogen Inc. (BIIB) for Potential Securities Fraud - Business Wire

Click here to get full coverage on Biogen Inc. (BIIB) exec exercises RSUs, uses shares for taxes - Stock Titan

Biogen Inc. (BIIB) exec exercises RSUs, uses shares for taxes  Stock Titan

Biogen Inc. (BIIB) exec exercises RSUs, uses shares for taxes - Stock Titan

Click here to get full coverage on Biogen (BIIB) Q1 2026 earnings summary - Quartr

Biogen (BIIB) Q1 2026 earnings summary  Quartr

BIIB

Price Chart

Key Statistics

Technicals

About BIIB

Latest News

BIIB Stock: Biogen Strengthens Immunology Pipeline In Up To $1B RayThera Deal - Stocktwits

Biogen pays up to $1B to add RayThera immunology assets - Stock Titan

Biogen (BIIB) to Acquire RayThera Inc. for Up to $1 Billion - GuruFocus

Advanced Charts

Top Gainers

Top Losers